JS Link, Inc.
KOSDAQ-listed genomics company offering the EGIS genome analysis and DNAGPS personal genome services, also active in forensic identification projects.
As of 2026-10-10, JS Link, Inc. has 3 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2011, JS Link specializes in genome analysis services. It offers EGIS, a genome analysis service for researchers, and DNAGPS, a personal genome analysis service for the general public, alongside a biobank for storing human-derived biological materials and AccuID, a forensic personal identification service. Personal genome analysis allows direct-to-consumer (DTC) service for 12 items designated on June 30, 2016; its biobank partners with health checkup centers at four general hospitals; and AccuID has participated in projects such as the 2018 Jeju April 3 incident remains-excavation project.
Products & technology
- EGISGenome analysis service for researchers
- DNAGPSPersonal genome analysis service for the general public predicting disease risk
- BiobankStorage and quality control of human-derived biological materials
- AccuIDForensic personal identification service
R&D and key agreements
Source: DART corporate disclosure유전체 대량분석기술 및 한국인 유전정보 DB구축 · 20여년 연구개발, 다수 논문·특허 출원 · Some R&D outcomes have been commercialized as the EGIS product
Key disclosures
KRX KIND via OpenDARTShow 4 more events
Publications
PubMed · affiliation-matched- Genome-Wide Risk Assessment and Clinical Prediction of Iodinated Contrast Media-Induced Anaphylaxis.
Allergy, asthma & immunology research · 2026-09 · Chung SJ, Shin E, Kim YS 외 9
- MetaCancerDB: a database of site-specific RNA-miRNA correlations in cancer metastasis.
Database : the journal of biological databases and curation · 2026-01 · Cho M, Park B, Han K
- Cohort profile update: the Korean Cancer Prevention Study-II (KCPS-II) biobank.
Epidemiology and health · 2025-01 · Kimm H, Jung KJ, Spiller W 외 5
Patents
KIPRIS · applicant-matchedPublished · 2026-06 · Application 1020260112473
Published · 2025-12 · Application 1020250214940
Published · 2025-12 · Application 1020250214920
Withdrawn · 2025-12 · Application 1020250214929
Published · 2025-12 · Application 1020250214935
Published · 2025-11 · Application 1020250185705
Published · 2025-11 · Application 1020250185837
Published · 2025-11 · Application 1020250169735
Published · 2025-10 · Application 1020250151895
Registered · 2025-10 · Application 1020250144565
Show 20 more patents
Published · 2025-08 · Application 1020250114273
Published · 2025-08 · Application 1020250114270
Registered · 2022-09 · Application 1020220120961
Registered · 2022-09 · Application 1020220121002
Registered · 2022-09 · Application 1020220120995
Withdrawn · 2018-08 · Application 1020180090979
Rejected · 2018-07 · Application 1020180079505
Withdrawn · 2016-10 · Application 1020160129078
Withdrawn · 2015-06 · Application 1020150091514
Withdrawn · 2013-01 · Application 1020130001241
Expired · 2012-02 · Application 1020120020982
Expired · 2012-02 · Application 1020120020983
Expired · 2011-07 · Application 1020110068563
Registered · 2010-01 · Application 1020100005221
Registered · 2009-06 · Application 1020090056168
Expired · 2009-02 · Application 1020090015867
Expired · 2008-11 · Application 1020080109058
Expired · 2003-11 · Application 1020037015424
Expired · 2003-05 · Application 1020030028278
Expired · 2000-12 · Application 1020000072424
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot42
- AnthropicClaudeBot2
- GoogleGoogleOther1
- PerplexityPerplexityBot1
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for JS Link, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition